The potential sale of its 88% stake in Bausch + Lomb could generate billions for creditors and shareholders of the indebted ...

It was quite a busy and eventful day for the company.

Bausch Health has recently changed its strategy for Bausch + Lomb, looking to sell the segment which has a market capitalization of nearly $8 billion. The potential sale of Bausch + Lomb is a break ...

Bullish option flow detected in Bausch Health (BHC) with 5,026 calls trading, 2x expected, and implied vol increasing over 2 ...

Key Takeaways Bausch + Lomb shares surged Monday following reports Blackstone and TPG are considering teaming up to buy the ...

Bausch & Lomb (NYSE:BLCO) jumped 9% in premarket trading on a report that private equity firms TPG (TPG) and Blackstone (BX) ...

Bausch Health faces $21 billion in debt, with $10 billion due by 2027 and a $2.4 billion loan due next year. Private equity ...

Evercore ISI upgraded shares of Bausch Health Companies (TSE:BHC – Free Report) to a hold rating in a research note published ...

On Oct. 4, The Paso Robles Daily News first broke the story, “Paso Robles city manager files complaint against city ...

Bausch Health Companies Inc. ( NYSE:BHC ) shareholders should be happy to see the share price up 26% in the last ...

Evercore ISI upgraded shares of Bausch + Lomb (NYSE:BLCO – Free Report) from an in-line rating to an outperform rating in a ...

The FDA granted approval to the enVista Envy full range of vision IOLs following Canadian approval in May 2024.